Posting of Annual Report and Accounts
08 May 2012
Instem plc
("Instem", the "Company" or the "Group")
Posting of Annual Report and Accounts
Notice of Annual General Meeting
Total Voting Rights
Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, announces that on 27 April 2012, it posted to shareholders its Annual Report and Accounts for the year ended 31 December 2011, together with the Notice of the Annual General Meeting to be held at 12.00 noon on Tuesday 22 May, 2012 at the offices of Baker Tilly UK Audit LLP, 3 Hardman Street, Manchester M3 3HF.
Copies of the Annual Report and Accounts are available on Instem's website at: http://investors.instem.com/.
The Company’s issued share capital consists of 11,764,658 ordinary shares with a nominal value of 10p each ('Ordinary Shares'). This figure reflects a discrepancy of 1 Ordinary Share against the figure previously stated. Application has been made to the London Stock Exchange for the additional 1 new Ordinary Share, which ranks pari passu with existing Ordinary Shares, to be admitted to trading on AIM as soon as is practicable.
The Company does not hold any Ordinary Shares in Treasury and each Ordinary Share carries one voting right. Therefore, the total number of voting rights in the Company is 11,764,658.
The figure of 11,764,658 may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.
For further information, please contact:
| Instem plc | www.instem.com |
| Phil Reason, CEO | +44 (0) 1785 825600 |
| Nigel Goldsmith, CFO | |
| N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Richard Lindley | |
| Nick Owen | |
| James White | |
| Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
| Paul Cornelius | or instem@walbrookpr.com |
| Sam Allen | |
| Helen Cresswell | |
| Paul Whittington |
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.